Abstract
Introduction: Type 2 diabetes (T2D) and cardiovascular disease (CVD) risk associate with ferritin and percent transferrin saturation (%TS) levels. However, increased risk has been observed at levels considered within the “normal range” for these markers.
Objective: To define normative ferritin and %TS levels associated with T2D and CVD risk. Methods: Six-monthly ferritin, %TS and hemoglobin levels from 1,277 iron reduction clinical trial participants with CVD (peripheral arterial disease, 37% diabetic) permitted pair-wise analysis using Loess Locally Weighted Smoothing plots. Curves showed continuous quantitative ferritin, hemoglobin (reflecting physiologic iron requirements), and %TS (reflecting iron transport and sequestration) levels over a wide range of values. Inflection points in the curves were compared to ferritin and %TS levels indicating increased T2D and CVD risk in epidemiologic and intervention studies. Results: Increasing ferritin up to about 80 ng/mL and %TS up to about 25% TS corresponded to increasing hemoglobin levels, and minimal T2D and CVD risk. Displaced Loess trajectories reflected lower hemoglobin levels in diabetics compared to non-diabetics. Ferritin levels up to about 100 ng/mL paralleled proportionately increasing %TS levels up to about 55%TS corresponding to further limitation of T2D and CVD risk. Ferritin levels over 100 ng/mL did not associate with hemoglobin levels and coincided with increased T2D and CVD risk. Conclusions: Recognition of modified normal ranges for ferritin from about 15 ng/mL up to about 80- 100 ng/mL and %TS from about 15% up to about 25-55% may improve the value of iron biomarkers to assess and possibly lower T2D and CVD risk.Keywords: Iron, ferritin, transferrin, diabetes, normal values, cardiovascular.
Current Diabetes Reviews
Title:Ferritin and Percent Transferrin Saturation Levels Predict Type 2 Diabetes Risk and Cardiovascular Disease Outcomes
Volume: 13 Issue: 4
Author(s): Leo R. Zacharski*, Galina Shamayeva , Bruce K. Chow and Ralph G. DePalma
Affiliation:
- Research Service, Department of Veterans Affairs Medical Center, White River Jct., Vermont,United States
Keywords: Iron, ferritin, transferrin, diabetes, normal values, cardiovascular.
Abstract: Introduction: Type 2 diabetes (T2D) and cardiovascular disease (CVD) risk associate with ferritin and percent transferrin saturation (%TS) levels. However, increased risk has been observed at levels considered within the “normal range” for these markers.
Objective: To define normative ferritin and %TS levels associated with T2D and CVD risk. Methods: Six-monthly ferritin, %TS and hemoglobin levels from 1,277 iron reduction clinical trial participants with CVD (peripheral arterial disease, 37% diabetic) permitted pair-wise analysis using Loess Locally Weighted Smoothing plots. Curves showed continuous quantitative ferritin, hemoglobin (reflecting physiologic iron requirements), and %TS (reflecting iron transport and sequestration) levels over a wide range of values. Inflection points in the curves were compared to ferritin and %TS levels indicating increased T2D and CVD risk in epidemiologic and intervention studies. Results: Increasing ferritin up to about 80 ng/mL and %TS up to about 25% TS corresponded to increasing hemoglobin levels, and minimal T2D and CVD risk. Displaced Loess trajectories reflected lower hemoglobin levels in diabetics compared to non-diabetics. Ferritin levels up to about 100 ng/mL paralleled proportionately increasing %TS levels up to about 55%TS corresponding to further limitation of T2D and CVD risk. Ferritin levels over 100 ng/mL did not associate with hemoglobin levels and coincided with increased T2D and CVD risk. Conclusions: Recognition of modified normal ranges for ferritin from about 15 ng/mL up to about 80- 100 ng/mL and %TS from about 15% up to about 25-55% may improve the value of iron biomarkers to assess and possibly lower T2D and CVD risk.Export Options
About this article
Cite this article as:
Zacharski R. Leo *, Shamayeva Galina , Chow K. Bruce and DePalma G. Ralph , Ferritin and Percent Transferrin Saturation Levels Predict Type 2 Diabetes Risk and Cardiovascular Disease Outcomes, Current Diabetes Reviews 2017; 13 (4) . https://dx.doi.org/10.2174/1573399813666170504163138
DOI https://dx.doi.org/10.2174/1573399813666170504163138 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Targeting of NLRP3 Inflammasomes by Natural Products and Pharmaceuticals: A Novel Mechanistic Approach for Inflammatory Diseases
Current Medicinal Chemistry Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Current Pharmaceutical Design Inwardly Rectifying Potassium Channels in the Regulation of Vascular Tone
Current Drug Targets Endothelin Receptor Antagonists as Disease Modifiers in Systemic Sclerosis
Inflammation & Allergy - Drug Targets (Discontinued) Genetic Variation in the β2-Adrenergic Receptor: Impact on Intermediate Cardiovascular Phenotypes
Current Pharmacogenomics and Personalized Medicine Treating Dyslipidemias: Is Inflammation the Missing Link?
Medicinal Chemistry A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
Current Pharmaceutical Design Gut Microbiota in Vascular Disease: Therapeutic Target?
Current Vascular Pharmacology New and Promising Chemotherapeutics for Emerging Infections Involving Drug-resistant Non-albicans Candida Species
Current Topics in Medicinal Chemistry A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure
Current Vascular Pharmacology Pulmonary Vasodilators in the Management of Low Cardiac Output Syndrome After Pediatric Cardiac Surgery
Current Vascular Pharmacology Hormone Replacement Therapy and Stroke
Current Vascular Pharmacology Prevalence of HTN in Iran: Meta-analysis of Published Studies in 2004-2018
Current Hypertension Reviews How Should Serum Uric Acid Concentrations be Interpreted in Patients with Hypertension?
Current Hypertension Reviews Strategies of Functional Foods Promote Sleep in Human Being
Current Signal Transduction Therapy Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design Editorial from Guest Editor: Current Management of Sleep Apnea and Comorbidities
Current Respiratory Medicine Reviews SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Imaging of Vascular Thrombosis
Current Molecular Imaging (Discontinued)